Cardinal Health (NYSE:CAH) subsidiary Cordis this week released an urgent field safety notice recalling its S.M.A.R.T. Flex vascular stent systems in sizes 5x200mm and 6x200mm over deployment issues. The company is recalling the devices over reports of deployment difficulty with the devices in the 2 particular sizes. The most commonly reported deployment issue is the inability to deploy […]
Cordis Corp.
Appeals court upholds Patent Office’s invalidity ruling on J&J stents patent
A federal appeals court yesterday upheld a patent board decision invalidating portions of a Johnson & Johnson (NYSE:JNJ) patent covering drug-eluting stents in a case that dates back to 2009. Wyeth, now part of Pfizer (NYSE:PFE), and onetime J&J subsidiary Cordis (which became a part of Cardinal Health in October 2015), sued Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX), alleging […]
Cardinal Health inks 4 new distro agreements
Cardinal Health (NYSE:CAH) today announced 4 new strategic distribution agreements, looking to expand its product portfolio with new coronary stents and percutaneous transluminal coronary angioplasty balloon catheters. “In the past year, since becoming a Cardinal Health company, we have executed several key strategic collaborations that strengthen the Cordis product and solutions offering in interventional cardiology. We […]
Cordis recalls Precise Pro RX carotid stent over separation issues
Cardinal Health (NYSE:CAH) subsidiary Cordis recently revealed a voluntary recall of its Precise Pro RX nitinol carotid stent system based on issues with shaft separation during stent deployment. The issue was discovered after the company received complaints about separation difficulties with the stent, which is indicated for use in patients with stenotic lesions of the carotid artery, […]
Cardinal Health’s Cordis gets back in the drug-eluting stent game with Biosensors deal
Cardinal Health (NYSE:CAH) said today that its Cordis subsidiary is getting back into the drug-eluting stent game via an overseas distribution agreement with Biosensors International (PINK:BSNRY). The deal calls for Cordis to sell the BioFreedom, BioMatrix NeoFlex, BioMatrix Alpha and Chroma stents made by Biosensors in Europe, the Middle East, Australia and New Zealand. Cordis said it plans to gradually […]
Fonar taps MR scan inventor and founder’s son as CEO | Personnel Moves
Fonar Corp (NSDQ:FONR) said yesterday it named Timothy Damadian, son of magnetic resonance scanning inventor and company founder Dr. Raymond Damadian, as its new president and CEO. The younger Damadian worked with Fonar for 16 years, eventually becoming veep of operations. He formed Fonar subsidiary Health Management Corporation of America, which manages medial and diagnostic […]
Cordis touts 4-year data on Incraft AAA stent graft
Cordis Corp. said today that 4-year data from a trial of its Incraft abdominal aortic aneurysm stent graft system showed it “performed well” in patients suffering from AAAs 4 years after treatment. Data from the study was presented at the VEITHsymposium in New York City this week. The multi-center, open-label prospective Innovation trial reported a 97% […]
Wyeth, Cordis bury the hatchet in stent patent spat with Abbott, Boston Scientific
A quartet of medical companies agreed yesterday to bury the hatchet in their 6-year-old battle over the patent covering drug-eluting stent technology. Wyeth, now part of Pfizer (NYSE:PFE), and onetime Johnson & Johnson (NYSE:JNJ) subsidiary Cordis (which this week became a part of Cardinal Health), sued Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) in 2009, alleging that […]
Cardinal Health closes $1.94b Cordis buy
Cardinal Health (NYSE:CAH) said yesterday it closed its $1.94 billion buy of Johnson & Johnson‘s (NYSE:JNJ)’s Cordis stent-making arm. The New Brunswick, N.J.-based healthcare giant announced the deal to pick up the cardiology and endovascular business from J&J in March The massive acquisition, which is worth some $1.59 billion net of tax benefits, offers annual synergies in […]
Cordis releases expanded range of CTO treatment catheters
Cordis Corporation said Monday it is releasing an expanded line of catheters designed to treat and cross chronic total occlusions. The previous Johnson & Johnson (NYSE:JNJ) subsidiary, recently sold to Cardinal Health (NYSE:CAH) said it will bring the Outback Elite re-entry catheter to the U.S., Japan and Europe, and the Elitecross Support catheter to the U.S. “New and […]
J&J accepts binding offer from Cardinal Health for Cordis unit
Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer worth about $2 billion for its Cordis stent-making arm from Cardinal Health (NYSE:CAH). The New Brunswick, N.J.-based healthcare giant said it expects the deal to close “towards the end of 2015.” The $1.94 billion deal, which is worth some $1.59 billion net of tax benefits, offers […]